Jane F Barlow - Net Worth and Insider Trading

Jane F Barlow Net Worth

The estimated net worth of Jane F Barlow is at least $93 dollars as of 2024-11-13. Jane F Barlow is the Director of TherapeuticsMD Inc and owns about 63 shares of TherapeuticsMD Inc (TXMD) stock worth over $93. Details can be seen in Jane F Barlow's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jane F Barlow has not made any transactions after 2019-08-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jane F Barlow

Jane F Barlow Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jane F Barlow owns 5 companies in total, including Momenta Pharmaceuticals Inc (MNTA) , TherapeuticsMD Inc (TXMD) , and Viracta Therapeutics Inc (VIRX) among others .

Click here to see the complete history of Jane F Barlow’s form 4 insider trades.

Insider Ownership Summary of Jane F Barlow

Ticker	Comapny	Transaction Date	Type of Owner
MNTA	Momenta Pharmaceuticals Inc	2020-10-01	director
TXMD	TherapeuticsMD Inc	2019-08-12	director
VIRX	Viracta Therapeutics Inc	2021-08-14	director
		2021-02-08	director
		2022-04-11	director

Jane F Barlow Latest Holdings Summary

Jane F Barlow currently owns a total of 1 stock. Jane F Barlow owns 63 shares of TherapeuticsMD Inc (TXMD) as of August 12, 2019, with a value of $93.

Latest Holdings of Jane F Barlow

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
TXMD	TherapeuticsMD Inc	2019-08-12	63	1.48	93

Holding Weightings of Jane F Barlow

Jane F Barlow Form 4 Trading Tracker

According to the SEC Form 4 filings, Jane F Barlow has made a total of 0 transactions in TherapeuticsMD Inc (TXMD) over the past 5 years. The most-recent trade in TherapeuticsMD Inc is the acquisition of 63 shares on August 12, 2019, which cost Jane F Barlow around $9,998.

Insider Trading History of Jane F Barlow

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jane F Barlow Trading Performance

GuruFocus tracks the stock performance after each of Jane F Barlow's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jane F Barlow is -8.08%. GuruFocus also compares Jane F Barlow's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jane F Barlow within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jane F Barlow's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jane F Barlow

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	12.79
Relative Return to S&P 500(%)	8.39

Jane F Barlow Ownership Network

Ownership Network List of Jane F Barlow

No Data

Ownership Network Relation of Jane F Barlow

Jane F Barlow Owned Company Details

What does Momenta Pharmaceuticals Inc do?

Who are the key executives at Momenta Pharmaceuticals Inc?

Jane F Barlow is the director of Momenta Pharmaceuticals Inc. Other key executives at Momenta Pharmaceuticals Inc include Chief Legal Officer Alejandra Carvajal , Chief Scientific Officer Anthony M. Manning , and SVP & Chief Medical Officer Santiago Arroyo .

Momenta Pharmaceuticals Inc (MNTA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Momenta Pharmaceuticals Inc (MNTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Momenta Pharmaceuticals Inc (MNTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Momenta Pharmaceuticals Inc (MNTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Momenta Pharmaceuticals Inc Insider Transactions

No Available Data

What does TherapeuticsMD Inc do?

Who are the key executives at TherapeuticsMD Inc?

Jane F Barlow is the director of TherapeuticsMD Inc. Other key executives at TherapeuticsMD Inc include General Counsel Marlan D Walker , Principal Financial Officer Joseph Ziegler , and CAO and VP of Finance Michael C Donegan .

TherapeuticsMD Inc (TXMD) Insider Trades Summary

Over the past 18 months, Jane F Barlow made no insider transaction in TherapeuticsMD Inc (TXMD). Other recent insider transactions involving TherapeuticsMD Inc (TXMD) include a net purchase of 5,294 shares made by Collins Cooper C. , and a net sale of 19,050 shares made by Marlan D Walker .

In summary, during the past 3 months, insiders sold 0 shares of TherapeuticsMD Inc (TXMD) in total and bought 5,294 shares, with a net purchase of 5,294 shares. During the past 18 months, 19,050 shares of TherapeuticsMD Inc (TXMD) were sold and 5,294 shares were bought by its insiders, resulting in a net sale of 13,756 shares.

TherapeuticsMD Inc (TXMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

TherapeuticsMD Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Jane F Barlow is the director of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Jane F Barlow made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

What does ContraFect Corp do?

Who are the key executives at ContraFect Corp?

Jane F Barlow is the director of ContraFect Corp. Other key executives at ContraFect Corp include VP Finance Michael Messinger , General Counsel Natalie Bogdanos , and Chief Medical Officer Cara M Cassino .

ContraFect Corp (CFRXQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ContraFect Corp (CFRXQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ContraFect Corp (CFRXQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ContraFect Corp (CFRXQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

ContraFect Corp Insider Transactions

No Available Data

What does Sera Prognostics Inc do?

Who are the key executives at Sera Prognostics Inc?

Jane F Barlow is the director of Sera Prognostics Inc. Other key executives at Sera Prognostics Inc include General Counsel Benjamin Jackson , Chief Financial Officer Austin Aerts , and Chief Scientific Officer John J. Boniface .

Sera Prognostics Inc (SERA) Insider Trades Summary

Over the past 18 months, Jane F Barlow made no insider transaction in Sera Prognostics Inc (SERA). Other recent insider transactions involving Sera Prognostics Inc (SERA) include a net sale of 147,717 shares made by John J. Boniface , a net sale of 49,324 shares made by Austin Aerts , and a net sale of 155,242 shares made by Zhenya Lindgardt .

In summary, during the past 3 months, insiders sold 67,941 shares of Sera Prognostics Inc (SERA) in total and bought 0 shares, with a net sale of 67,941 shares. During the past 18 months, 441,312 shares of Sera Prognostics Inc (SERA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 441,312 shares.

Sera Prognostics Inc (SERA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sera Prognostics Inc Insider Transactions

No Available Data

Jane F Barlow Mailing Address

Above is the net worth, insider trading, and ownership report for Jane F Barlow. You might contact Jane F Barlow via mailing address: 6800 Broken Sound Parkway Nw, 3rd Floor, Boca Raton Fl 33487.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.